30 Jun, 2020– Can-Fite BioPharma Ltd.
today announced that the final data analysis from its Phase II study of
Namodenoson in the treatment of patients with non-alcoholic fatty liver disease
(NAFLD) with or without non-alcoholic steatohepatitis (NASH) has been
completed. As a whole, the data show that Namodenoson at the 25 mg dose
produced statistically significant results in all measures of efficacy, while
also having a strong safety profile and well tolerated.
“We are very pleased with these compelling data. The next clinical trial
protocol to advance Namodenoson in the treatment of NASH and NAFLD is now being
developed. With the clear need for approved drugs in this indication, I believe
distribution partners for Can-Fite will likely take notice of these results,”
stated Prof. Rifaat Safadi of Hadassah Medical Center, the Principal
Investigator of the study.
The original website link:
https://ir.canfite.com/press-releases/detail/913/can-fite-announces-final-data-analysis-from-phase-ii-nash-study-highly-significant-and-sustained-reduction-in-liver-fat-volume-throughout-study-period